GC Biopharma Corp. (KRX:006280)
South Korea · Delayed Price · Currency is KRW 119,800
-7,100 (-5.59%)
Last updated: Jun 8, 2026, 2:03 PM KST
GC Biopharma Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, GC Biopharma stock has a consensus rating of "Buy" and an average price target of ₩209,400. The average 1-year stock price forecast is 74.79% higher than the current stock price, while the lowest is ₩190,000 (+58.60%) and the highest is ₩230,000 (+91.99%).
Price Target: ₩209,400 (+74.79%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for GC Biopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 4 | 4 |
| Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 11 | 11 | 10 | 10 |
Financial Forecast
Revenue This Year
2.03T
from 1.99T
Increased by 2.11%
Revenue Next Year
2.14T
from 2.03T
Increased by 5.31%
EPS This Year
9.19K
from -410.00
EPS Next Year
3.45K
from 9.19K
Decreased by -62.51%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.1T | ||
| Avg | 2.0T | ||
| Low | 2.0T |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.1% | ||
| Avg | 2.1% | ||
| Low | -0.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 19,168.00 | ||
| Avg | 9,192.33 | ||
| Low | 3,677.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |